Cardiovascular Systems Inc

Cardiovascular Systems — Q3 FY2021 Earnings Presentation

12 slides from Cardiovascular Systems's earnings presentation, May 6, 2021

  1. Slide 1: Q3 FY21 Earnings Supplement

    ©2021 Cardiovascular Systems, Inc. All Rights Reserved. Q3 FY21 Earnings Supplement May 6, 2021

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Q3 FY21 Worldwide Revenues of $63.3 Million, Highlights

    3.4% Year Over Year Increase Q3 FY21 Worldwide Revenues of $63.3 Million *Excludes $20.9M financing obligation for lease payments on company headquarters Q3 FY21 Revenue Breakdown Worldwide Peripheral $42.3 (-0.8%) Worldwide Coronary $21.0 (+13.1%) Worldwide Peripheral Worldwide Coronary ($ in milli

  4. Slide 4: Q3 FY21: U.S. Peripheral

    Q3 FY21: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, ViperCath and WIRION Strong growth i

  5. Slide 5: Q3 FY21: U.S. Coronary

    Q3 FY21: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes coronary orbital atherectomy devices, Coronary Guidewire, ViperSlide and other 3 Includes Sapphire angioplasty balloons and Teleport microcatheters Steady year-over-year

  6. Slide 6: Q3 FY21: International

    Q3 FY21: International Strong growth in Japan and EU launch underway 6 International revenue increased 20.5% year over year • International revenue increased 62.7% sequentially • Record case volume and revenue in the quarter • Received CE Mark for Diamondback 360® Coronary OAS in January 2021 • Succ

  7. Slide 7: Q3 FY21 vs. Q2 FY21 and Q3 FY20

    Q3 FY21 vs. Q2 FY21 and Q3 FY20 Dollars in thousands 7 Q3 FY21 Quarter Over Quarter Change Year Over Year Change Worldwide Revenue $63,273 -1.4% 3.4% Worldwide Peripheral Revenue $42,295 -3.8% -0.8% Worldwide Coronary Revenue $20,978 3.8% 13.1% US Revenue $59,593 -3.7% 2.5% US Peripheral Revenue $42

  8. Slide 8: Q3 FY21: Select Financial Information

    Q3 FY21: Select Financial Information Dollars in thousands, except earnings per share 8 Q3 FY21 Q2 FY21 Q/Q Change Fav (Unfav) Q3 FY20 Y/Y Change Fav (Unfav) Net revenues $63,273 $64,169 $(896) $61,175 $2,098 Cost of goods sold 14,013 13,920 (93) 12,225 (1,788) Gross Margin 77.9% 78.3% Decreased 40B

  9. Slide 9: Q4 FY21: Guidance

    Q4 FY21: Guidance 9 For the fiscal 2021 fourth quarter ending June 30, 2021, CSI anticipates: Revenue of $67 million to $70 million; Gross profit as a percentage of revenues in the 70% to 71% range*; Operating expenses in a range of $53.5 million to $55.5 million; Net loss in a range of $6 million t

  10. Slide 10: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 10 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense

  11. Slide 11: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 [email protected] CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2021 Cardiovascular Systems, Inc. OrbusNeich®, Teleport® and Sapphire® are trademarks of Or

  12. Slide 12: Cardiovascular Systems, Inc.

    CARDIOVASCULAR SYSTEMS, INC. cSi www.csi360.com

Cardiovascular Systems — Q3 FY2021 Earnings Presentation on 6ix